Literature DB >> 16752285

Revision total hip arthroplasty in juvenile chronic arthritis: 17 revisions in 11 patients followed for 4-12 years.

Stuart B Goodman1, Kwang-Jun Oh, Susanna Imrie, Katherine Hwang, Mychelle Shegog.   

Abstract

BACKGROUND: Revision total hip arthroplasty (THA) in patients with juvenile chronic arthritis (JCA) is complicated by the young age of the patient, poor bone stock and small physical proportions. We report the complications and outcome of a prospective series of 17 revision THAs in Charnley class C JCA patients.
METHODS: 15 acetabular components and 10 femoral components were revised. 13 cementless cups, 2 reconstruction/roof rings and cemented cups, and 4 cemented and 6 cementless femoral stems were implanted. 2 proximal femoral allografts and 1 strut allograft were used. Age at revision was 32 (21-53) years. Follow-up averaged 7 (4-12) years.
RESULTS: 2 patients with cemented femoral stems developed loosening, osteolysis and fracture. Both were successfully revised to long-stem cementless implants with strut/proximal femoral allografts. 1 loose, worn cementless cup with osteolysis was revised. 1 patient with a peri-operative infection and late acetabular fracture had a loose, non-revised cementless cup. 1 case of sciatic nerve palsy occurred after revision using a reconstruction ring. 1 late infection necessitated resection arthroplasty. Harris hip scores improved from 53 (34-85) to 76 (47-96).
INTERPRETATION: Revision THA in JCA has a substantial complication rate, even in experienced hands. The problem of obtaining long-term stable fixation, osteolysis, and replenishment of lost bone stock are major difficulties.

Entities:  

Mesh:

Year:  2006        PMID: 16752285     DOI: 10.1080/17453670610045975

Source DB:  PubMed          Journal:  Acta Orthop        ISSN: 1745-3674            Impact factor:   3.717


  9 in total

1.  Alumina-on-alumina THA in patients with juvenile idiopathic arthritis: a 5-year followup study.

Authors:  Ana Cruz-Pardos; Eduardo García-Rey; Eduardo García-Cimbrelo; Jose Ortega-Chamarro
Journal:  Clin Orthop Relat Res       Date:  2011-08-31       Impact factor: 4.176

Review 2.  [Juvenile rheumatoid diseases: Endoprosthetic care of destroyed hip joints].

Authors:  S Rehart; M Henniger
Journal:  Orthopade       Date:  2015-07       Impact factor: 1.087

3.  In vivo testing of canine prosthetic femoral components with HA-Ti ladder-type coating on vacuum plasma-sprayed Ti substrate.

Authors:  Xian-Lin Zeng; Jing-Feng Li; Shu-Hua Yang; Qi-Xin Zheng; Zhen-Wei Zou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-08-01

4.  [Periprosthetic fractures in patients with rheumatoid arthritis].

Authors:  G Pap; H W Neumann
Journal:  Z Rheumatol       Date:  2007-02       Impact factor: 1.372

5.  Osteogenic activity of locally applied small molecule drugs in a rat femur defect model.

Authors:  Jessica A Cottrell; Francis M Vales; Deborah Schachter; Scott Wadsworth; Rama Gundlapalli; Rasesh Kapadia; J Patrick O'Connor
Journal:  J Biomed Biotechnol       Date:  2010-06-16

Review 6.  Total joint replacement in childhood arthritis.

Authors:  Han Jo Kim; Barbara Kahn; Mark P Figgie
Journal:  Curr Rheumatol Rep       Date:  2008-04       Impact factor: 4.592

7.  High complication rate in revision total hip arthroplasty in juvenile idiopathic arthritis.

Authors:  Stuart B Goodman; Katherine Hwang; Susanna Imrie
Journal:  Clin Orthop Relat Res       Date:  2014-02       Impact factor: 4.176

8.  Revision of failed hip resurfacing to total hip arthroplasty rapidly relieves pain and improves function in the early post operative period.

Authors:  Nemandra A Sandiford; Sarah K Muirhead-Allwood; John A Skinner
Journal:  J Orthop Surg Res       Date:  2010-11-29       Impact factor: 2.359

9.  In vitro testing of femoral impaction grafting with porous titanium particles: a pilot study.

Authors:  René Aquarius; Luc Walschot; Pieter Buma; Berend Willem Schreurs; Nico Verdonschot
Journal:  Clin Orthop Relat Res       Date:  2009-01-13       Impact factor: 4.176

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.